FDA’s Trial Data Disclosure Policy Diverges From EMA’s By Masking Products
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA explains that it would de-identify and mask data to be made publicly available while EMA’s plan involves release of data related to a specific approved product or application.